Skip To Main Content
Určeno pro odbornou veřejnost
Campus
Campus
View Full Results

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
One minute to ignite new thinking in COPD

One minute to ignite new thinking in COPD

Understanding type 2 inflammation* may help shed light on why some patients continue to exacerbate. Watch this video to learn how.1

Číst více
Quality of life and symptom measurement in COPD Patients

Quality of life and symptom measurement in COPD Patients

Číst více
Role of type 2 Inflammation*

Role of type 2 Inflammation

Číst více
EADV24 Highlights

EADV24 Highlights

Číst více
EADV24 Highlights

EADV24 Highlights

Číst více
Choroby Gauchera i ASMD. Co zrobić by o nich pamiętać w praktyce lekarskiej?

Choroby Gauchera i ASMD. Co zrobić by o nich pamiętać w praktyce lekarskiej?

Objawy kliniczne: splenomegalia, małopłytkowość, niedokrwistość...

Objawy niespecyficzne, różnorodne...

Kiedy podejrzewać chorobę Gauchera w praktyce lekarza hematologa, pediatry?

Zapraszamy do obejrzenia dyskusji Ekspertów - Konferencja PTOiHD 2024.

Číst více
חיסון למניעת RSV

חיסון למניעת RSV

Číst více
Tọa Đàm Trực Tuyến Cập Nhật Các Tiến Bộ Trong Phẫu Thuật Thẩm Mỹ & Chấn Thương Chỉnh Hình - Vai Trò Của Alphachymotrypsine Trên Lâm Sàng

Tọa Đàm Trực Tuyến Cập Nhật Các Tiến Bộ Trong Phẫu Thuật Thẩm Mỹ & Chấn Thương Chỉnh Hình - Vai Trò Của Alphachymotrypsine Trên Lâm Sàng

Číst více
Program lekowy B.164. LECZENIE PACJENTÓW Z IMMUNOLOGICZNĄ ZAKRZEPOWĄ PLAMICĄ MAŁOPŁYTKOWĄ (ICD-10: M31.1)

Program lekowy B.164. LECZENIE PACJENTÓW Z IMMUNOLOGICZNĄ ZAKRZEPOWĄ PLAMICĄ MAŁOPŁYTKOWĄ (ICD-10: M31.1).

Serdecznie zapraszamy do zapoznania się z materiałem.

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Číst více